# Heart Failure Staging > Heart failure staging for NEET-PG Medicine: ACC/AHA stages A to D versus NYHA classes, ejection fraction categories and the four drug pillars. - Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/heart-failure-staging - Exam / course: NEET-PG · Subject: Medicine - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Heart Failure Staging", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/heart-failure-staging ## Direct answer Heart failure is staged by the ACC/AHA system into stages A to D — A: at risk with risk factors only; B: structural heart disease without symptoms; C: structural disease with current or previous symptoms; D: refractory failure needing advanced therapies — a one-way progression that guides therapy. The New York Heart Association (NYHA) classification grades symptoms from class I (no limitation) to class IV (symptoms at rest) and can fluctuate with treatment. Drug therapy for heart failure with reduced ejection fraction now rests on four pillars: an ARNI or ACE inhibitor, a beta blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor. ## What you must remember - The two systems contrasted: staging (A to D) reflects disease progression and cannot move backwards, while NYHA class (I to IV) reflects current symptoms and can improve or worsen. - Stage A: hypertension, diabetes, obesity, cardiotoxin exposure — treat risk factors; Stage B: structural disease without symptoms — add ACE inhibitor or ARB and beta blocker; Stage C: symptoms — full guideline-directed therapy; Stage D: refractory symptoms — inotropes, transplant or palliation. - Ejection fraction categories: reduced (HFrEF) 40 per cent or less, mildly reduced 41 to 49 per cent, preserved (HFpEF) 50 per cent or more — SGLT2 inhibitors benefit both reduced and preserved phenotypes. - Four pillars of HFrEF therapy: angiotensin receptor-neprilysin inhibitor (or ACE inhibitor/ARB), an evidence-based beta blocker (bisoprolol, metoprolol succinate, carvedilol), a mineralocorticoid receptor antagonist (spironolactone, eplerenone) and an SGLT2 inhibitor (dapagliflozin, empagliflozin) — start low and titrate early, in any order. - Diuretics relieve congestion but do not reduce mortality; loop diuretics are first choice for volume overload. - Devices: cardiac resynchronisation therapy for symptomatic patients with wide QRS (especially 150 ms or more with left bundle branch block) and ejection fraction 35 per cent or below; an implantable cardioverter-defibrillator for ejection fraction 35 per cent or less despite three months of optimal therapy. - Echocardiography is the single most useful investigation; natriuretic peptides help rule out heart failure in undifferentiated dyspnoea. - Common causes in India: ischaemic heart disease, hypertension, rheumatic valve disease and cardiomyopathies. ## One patient, both classification systems, then the prescription A 66-year-old man with a prior anterior infarct now has an ejection fraction of 32 per cent and breathlessness climbing one flight. He is stage C by ACC/AHA — structural disease with current symptoms — and NYHA class II today; with better therapy the class may improve, but he remains stage C for life. That contrast is the whole point: staging is the one-way street guiding therapy (A risk factors; B structural disease without symptoms; C symptoms, full therapy; D refractory), while NYHA is the fluctuating gauge. The echocardiogram also phenotyped him — 40 per cent or less reduced, 41 to 49 mildly reduced, 50 or more preserved — and his reduced phenotype earns the four pillars, titrated early in any order: Loop diuretics relieve congestion without touching mortality. Symptomatic with ejection fraction 35 per cent or below and QRS 150 ms or more with left bundle branch block, resynchronisation follows; a defibrillator waits for 35 per cent or less despite three months of optimal therapy. ## Where students slip The staging-versus-NYHA distinction carries the marks: "a stage C patient improves from NYHA III to NYHA II" is true, while "he reverts to stage B" is the false statement the options plant. The second slip is the pillar count — older lists with three pillars predate the SGLT2 inhibitor. The device thresholds are perennial: And the preserved-ejection-fraction stem is answered with diuretics, comorbidity control and an SGLT2 inhibitor — reaching for the reduced-EF armamentum in HFpEF is the deliberate distractor. ## Frequently asked questions ### What are the ACC/AHA stages of heart failure? A: risk factors only; B: structural disease without symptoms; C: structural disease with symptoms; D: refractory failure requiring advanced therapies. ### How does NYHA classification differ from staging? NYHA grades I to IV describe current symptoms and can improve with treatment, whereas ACC/AHA stages reflect disease progression and do not reverse. ### What are the four pillars of HFrEF drug therapy? An ARNI or ACE inhibitor, an evidence-based beta blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor. ### Which device suits a wide-QRS patient with low ejection fraction? Cardiac resynchronisation therapy, particularly with QRS 150 ms or more and left bundle branch block, alongside medical therapy. ### What is the role of diuretics? Symptomatic relief of congestion with loop diuretics first line — essential for comfort, but not proven to reduce mortality. ### How is HFpEF managed? Diuretics for congestion, aggressive control of hypertension, diabetes and atrial fibrillation, and an SGLT2 inhibitor to reduce hospitalisation.